Lara Sullivan's Net Worth

$9.44 Million

Estimate Recalculated Apr 15, 2024 03:12PM EST

Who is Lara Sullivan?

Lara Sullivan has an estimated net worth of $9.44 Million. This is based on reported shares across multiple companies, which include Pyxis Oncology, Inc., and REXAHN PHARMACEUTICALS, INC..

SEC CIK

Lara Sullivan's CIK is 0001769457

Past Insider Trading and Trends

2023 was Lara Sullivan's most active year for acquiring shares with 5 total transactions. Lara Sullivan's most active month to acquire stocks was the month of February. 2023 was Lara Sullivan's most active year for disposing of shares, totalling 8 transactions. Lara Sullivan's most active month to dispose stocks was the month of August. 2023 saw Lara Sullivan paying a total of $0.00 for 2,320,832 shares, this is the most they've acquired in one year. In 2023 Lara Sullivan cashed out on 1,273,586 shares for a total of $474,962.38, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Pyxis Oncology, Inc. (PYXS) Snapshot price: $3.7303

Chief Executive Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Mar 26
Form 4
-0.36%
-8.64K
$2.10
-$18,161.10
2.4M
Sep 14 - Sep 18
Form 4
-8.10%
-212.66K
$2.15
-$456,801.28
2.41M
Sep 11 - Sep 13
Form 4
+21.78%
469.48K
—
—
2.63M
Sep 7
Form 4
+48.43%
703.38K
—
—
2.16M
Mar 24
Form 4
+7.05%
95.68K
—
—
1.45M
Jan 3
Form 4
+30.28%
315.27K
—
—
1.36M
Apr 14
Form 4
+248.53%
742.57K
—
—
1.04M
Mar 31
Form 4
—
0
—
—
0
Oct 7
Form 3
—
0
—
—
0
No matching records found

REXAHN PHARMACEUTICALS, INC. (OCUP) Snapshot price: $2.58

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jun 6
Form 4
—
0
—
—
0
Feb 27
Form 3
—
0
—
—
0
No matching records found